Numerous variants of unknown significance (VUSs) exist in hereditary breast and ovarian
cancers. Although multiple methods have been developed to assess the significance of …

Rare exonic, non-truncating variants in known cancer susceptibility genes such as BRCA1
and BRCA2 are problematic for genetic counseling and clinical management of relevant …

Abstract Background Although BRCA1 or BRCA2 (BRCA1/2) genetic testing plays an
important role in determining treatment modalities in patients with hereditary breast and …

Mutations in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian
cancers, and therefore sequence analysis of both genes is routinely conducted in patients …

Germline mutations in the BRCA1 gene have been reported to increase the lifetime risk of
developing breast and/or ovarian cancer (BOC). By new sequencing technologies …

Over the years since the genetic testing of BRCA1 and BRCA2 has been conducted for
research and later introduced into clinical practice, a high number of missense variants have …

Ascertaining the clinical consequences of BRCA1 and BRCA2 variants of uncertain
significance (VUS) is currently indispensable for providing effective genetic counseling and …

Many variants of uncertain significance (VUS) have been identified in BRCA2 through
clinical genetic testing. VUS pose a significant clinical challenge because the contribution of …

Background Deleterious variants in the tumour suppressor BRCA1 are known to cause
hereditary breast and ovarian cancer syndrome (HBOC). Missense variants in BRCA1 pose …

Mutation of BRCA1 and BRCA2 is the most common cause of inherited breast and ovarian
cancer. Genetic screens to detect carriers of variants can aid in cancer prevention by …